- Joined
- Oct 3, 2024
- Messages
- 941
- Online time
- 4d 4h
- Reputation
- 1,237
Clinical trials investigating MDMA-assisted therapy (MDMA-AT) for social anxiety in autistic adults have shown promising results, indicating that the substance—when used in a controlled clinical setting—can help manage social anxiety symptoms that have previously been resistant to conventional treatments.
PubMed Central (PMC) (.gov) +1
Here is a summary of the current landscape based on clinical research as of early 2026:
Clinical Trials and Results for ASD
The Clinical Setting vs. Recreational Use
Here is a summary of the current landscape based on clinical research as of early 2026:
Clinical Trials and Results for ASD
- Initial Findings (2018): A pilot study published in Psychopharmacology conducted by Dr. Alicia Danforth and colleagues found that autistic adults with marked-to-severe social anxiety experienced durable improvements 6 months after two MDMA-assisted sessions. Participants reported increased feelings of empathy, ease of communication, and reduced distress in social situations.
- Mechanism: The trials showed that MDMA can foster intense empathy, reduce fear of social evaluation, and increase feelings of safety and authenticity.
- Focus on Social Anxiety: The aim is not to "cure" autism, but to treat social anxiety disorder (SAD), which is prevalent in roughly 1 in 4 autistic adults.
- Current Status (2026): While MDMA-assisted therapy for PTSD has moved further along (with Australia beginning to allow psychiatrist treatment in 2025/2026), research into its specific application for autism is continuing to expand to larger samples to verify these early findings.
Frontiers +6
The Clinical Setting vs. Recreational Use